News
Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback